Phase II Proof-of-Concept Trial of the Orexin Receptor Antagonist Filorexant (MK-6096) in Patients with Major Depressive Disorder.
Int J Neuropsychopharmacol 2017 Aug;20(8):613-618
Merck & Co., Inc., Kenilworth, New Jersey (Dr. Connor, Dr. Ceesay, Ms. Hutzelmann, Mr. Snavely, Dr. Lines, Dr. Herring, and Dr. Michelson); Duke University Hospital, Durham, North Carolina (Dr. Krystal); University of Texas Southwestern Medical Center, Dallas, Texas (Dr. Trivedi); University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania (Dr. Thase).

Randomized controlled trial of the CGRP receptor antagonist telcagepant for migraine prevention.
Neurology 2014 Sep 8;83(11):958-66. Epub 2014 Aug 8.
From Merck & Co., Inc. (T.W.H., K.M.C., Y.Z., J.K., X.F., C.L., D.M.), Whitehouse Station, NJ; Mercer University School of Medicine (E.P.), Savannah, GA; Department of Medicine (L.E.), Institute of Clinical Sciences, Lund University and Lund University Hospital, Sweden; Headache Group (P.J.G.), NHIR-Wellcome Trust Clinical Research Facility, King's College London, UK; and Department of Neurology (P.J.G.), University of California, San Francisco. T.W.H. is currently affiliated with AstraZeneca Pharmaceuticals LP, Wilmington, DE. X.F. is currently affiliated with Elan Corporation, Boston, MA.

A Phase II Dose-Ranging Study Evaluating the Efficacy and Safety of the Orexin Receptor Antagonist Filorexant (MK-6096) in Patients with Primary Insomnia.
Int J Neuropsychopharmacol 2016 08 12;19(8). Epub 2016 Aug 12.
Merck & Co., Inc., Kenilworth, NJ (Dr Connor, Ms Mahoney, Ms Jackson, Ms Hutzelmann, Dr Zhao, Dr Jia, Dr Snyder, Mr Snavely, Dr Michelson, and Dr Herring); Henry Ford Hospital, Detroit, MI (Dr Roth).Current affiliations: Biogen, Cambridge, MA (E.M.). Janssen Pharmaceutical Research and Development, Raritan, NJ (X.Z.). Eli Lilly and Company, Indianapolis, IN (N.J.).